{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:00:23Z","timestamp":1761181223970,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jbspin.2019.01.014","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:25:45Z","timestamp":1549002345000},"page":"699-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views"],"prefix":"10.1016","volume":"86","author":[{"given":"Ga\u00eblle","family":"Clavel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gabison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Semerano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2019.01.014_bib0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.revmed.2018.02.001","article-title":"Scleritis and systemic diseases: what should know the internist?","volume":"39","author":"Bielefeld","year":"2018","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0010","doi-asserted-by":"crossref","first-page":"6430953","DOI":"10.1155\/2018\/6430953","article-title":"Manifestation of clinical categories of ocular graft-versus-host disease","volume":"2018","author":"Qiu","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","article-title":"The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?","volume":"91","author":"Ho","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbspin.2017.06.004","article-title":"Efficacy and safety of biological DMARDs modulating B cells in primary Sj\u00f6gren's syndrome: Systematic review and meta-analysis","volume":"85","author":"Letaief","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0025","first-page":"393","article-title":"Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies","volume":"9","author":"Vignesh","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0454","article-title":"Therapy insight: scleritis and its relationship to systemic autoimmune disease","volume":"3","author":"Smith","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/ard.48.1.7","article-title":"Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study","volume":"48","author":"Erhardt","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0040","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0161-6420(84)34160-4","article-title":"Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression","volume":"91","author":"Foster","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jfo.2012.12.004","article-title":"Ocular manifestations of the potentially lethal rheumatologic and vasculitic disorders","volume":"36","author":"Foster","year":"2013","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jfo.2017.04.007","article-title":"Scleritis and episcleritis","volume":"40","author":"H\u00e9ron","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","article-title":"Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease","volume":"39","author":"Gaujoux-Viala","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbspin.2017.01.002","article-title":"Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: data from the French registry REGATE","volume":"85","author":"Terreaux","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0065","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2007.09.024","article-title":"Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis","volume":"145","author":"Lin","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.preteyeres.2013.02.004","article-title":"Scleritis: Immunopathogenesis and molecular basis for therapy","volume":"35","author":"Wakefield","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0075","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0161-6420(91)32280-2","article-title":"Immunopathology of scleritis","volume":"98","author":"Fong","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14656566.2013.772982","article-title":"Pharmacotherapy of scleritis: current paradigms and future directions","volume":"14","author":"Beardsley","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0110","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/bjophthalmol-2015-307462","article-title":"Efficacy and safety of immunosuppressive agents in the treatment of necrotising scleritis: a retrospective, multicentre study in Korea","volume":"100","author":"Jeon","year":"2016","journal-title":"British Journal of Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0115","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajo.2009.07.021","article-title":"Scleritis and systemic disease association in a community-based referral practice","volume":"148","author":"Raiji","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: a new treatment perspective","volume":"35","author":"de Fidelix","year":"2015","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0125","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3129\/i09-061","article-title":"Infliximab for the treatment of active scleritis","volume":"44","author":"Sen","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-620X.91271","article-title":"Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis","volume":"4","author":"Bawazeer","year":"2011","journal-title":"Oman J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12348-016-0107-y","article-title":"Refractory necrotizing scleritis successfully treated with adalimumab","volume":"6","author":"Lawuyi","year":"2016","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/09273948.2013.863944","article-title":"Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors","volume":"22","author":"Ragam","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.eye.6701457","article-title":"The successful use of infliximab in resistant relapsing polychondritis and associated scleritis","volume":"19","author":"Cazabon","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.eye.6701712","article-title":"Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis","volume":"19","author":"El-Shabrawi","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0165","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/rheumatology\/keh635","article-title":"Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy","volume":"44","author":"Ashok","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.rhu.0000249766.24780.95","article-title":"Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab","volume":"12","author":"Atchia","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0175","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00417-007-0634-1","article-title":"Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive therapy","volume":"245","author":"Weiss","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab therapy for the treatment of refractory ocular inflammatory disease","volume":"125","author":"Sobrin","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0185","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10384-008-0652-5","article-title":"Treating refractory scleritis with infliximab","volume":"53","author":"Ahn","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0190","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/j.1755-3768.2009.01546.x","article-title":"Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment","volume":"88","author":"Kontkanen","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0195","first-page":"212","article-title":"Infliximab treatment in a case of rheumatoid scleromalacia perforans","volume":"61","author":"Herrera-Esparza","year":"2009","journal-title":"Reumatismo"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0200","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/09273941003624914","article-title":"Infliximab in a patient with refractory necrotizing scleritis associated with relapsing polychondritis","volume":"18","author":"Jabbarvand","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000342842","article-title":"Combined infliximab and rituximab in necrotising scleritis","volume":"3","author":"Morarji","year":"2012","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0215","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0220","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09273948.2013.788724","article-title":"Rituximab therapy for refractory idiopathic scleritis","volume":"21","author":"Bogdanic-Werner","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0225","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/bjo.2008.147157","article-title":"Rituximab for treatment of scleritis associated with rheumatoid arthritis","volume":"93","author":"Chauhan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0230","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0235","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: a series of four cases","volume":"93","author":"Kurz","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0240","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease","volume":"122","author":"Joshi","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0245","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00417-015-3198-5","article-title":"Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's)","volume":"253","author":"Recillas-Gispert","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0250","first-page":"1","article-title":"Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener's)","author":"You","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0255","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajo.2015.12.032","article-title":"Rituximab in the treatment of refractory noninfectious scleritis","volume":"164","author":"Cao","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0260","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1111\/aos.12720","article-title":"Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis","volume":"93","author":"Tode","year":"2015","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0265","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/03009742.2016.1275774","article-title":"Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis","volume":"46","author":"Shimizu","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0270","doi-asserted-by":"crossref","first-page":"A204","DOI":"10.1016\/j.revmed.2018.03.179","article-title":"Efficacit\u00e9 du tocilizumab dans les scl\u00e9rites non n\u00e9crosantes r\u00e9fractaires. \u00c0 propos de 4 cas","volume":"39","author":"Sen\u00e9","year":"2018","journal-title":"Rev Medecine Intern"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0275","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2016.09.017","article-title":"Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: Results of a phase I\/II clinical trial","volume":"172","author":"Knickelbein","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2009.06.025","article-title":"Chronic herpes simplex scleritis: characterization of 9 cases of an underrecognized clinical entity","volume":"148","author":"Bhat","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0285","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7298026","article-title":"Peripheral ulcerative keratitis associated with autoimmune disease: pathogenesis and treatment","volume":"2017","author":"Cao","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0290","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.berh.2016.10.007","article-title":"The eye and inflammatory rheumatic diseases: the eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis","volume":"30","author":"Murray","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0295","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrrheum.2013.185","article-title":"Ocular inflammatory diseases associated with rheumatoid arthritis","volume":"10","author":"Artifoni","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.014_bib0300","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjophthalmol-2016-308838","article-title":"Management of severe and refractory Mooren's ulcers with rituximab","volume":"101","author":"Guindolet","year":"2017","journal-title":"Br J Ophthalmol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19300120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19300120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:55Z","timestamp":1761150355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X19300120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1297319X19300120"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.014","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}